argenx NV ADR (ARGX)vsQ32 Bio Inc (QTTB)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
QTTB
Q32 Bio Inc
$7.25
-0.68%
HEALTHCARE · Cap: $98.89M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 7784% more annual revenue ($4.24B vs $53.74M). QTTB leads profitability with a 55.5% profit margin vs 30.5%. QTTB trades at a lower P/E of 2.8x. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
QTTB
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Margin of Safety
+76.7%
Fair Value
$16.46
Current Price
$7.25
$9.21 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Attractively priced relative to earnings
Every $100 of equity generates 125 in profit
Keeps 56 of every $100 in revenue as profit
Strong operational efficiency at 85.4%
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : QTTB
The strongest argument for QTTB centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 55.5% and operating margin at 85.4%.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : QTTB
The primary concerns for QTTB are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while QTTB is a value play — different risk/reward profiles.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (63/100 vs 60/100), backed by strong 30.5% margins and 73.0% revenue growth. QTTB offers better value entry with a 76.7% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Q32 Bio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Q32 Bio Inc. is a pioneering biotechnology firm focused on developing innovative antibody-based therapies to address autoimmune diseases and enhance immune responses. Utilizing its proprietary technology platform, the company is advancing a robust pipeline of treatments designed to restore immune system balance. Backed by a seasoned management team and strategic collaborations, Q32 Bio is well-positioned to leverage its scientific expertise to meet significant unmet medical needs, thereby driving transformative advancements in healthcare and creating value for shareholders through sustained research and development initiatives.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?